Beyond lymph node staging: molecular predictors of outcome in breast cancer.
This article briefly reviews the exciting, yet unproven, reports of alternate methods of predicting outcomes in breast cancer and highlights new molecular methods of diagnosing, classifying, and treating this disease. The author starts by reviewing well-known factors in breast cancer with which all alternate methods of staging and predicting outcomes must be compared prospectively.
Sheldon
David G
DG
Section of Surgical Oncology, Geisinger Health System, 100 North Academy Avenue, MC 21-70, Danville, PA 17822-2170, USA. dgsheldon@geisinger.edu
D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology*; D005260:Female; D005819:Genetic Markers; D020022:Genetic Predisposition to Disease; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis / Q000235:genetics*; D009367:Neoplasm Staging; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D021701:Sentinel Lymph Node Biopsy; D016896:Treatment Outcome
D005819:Genetic Markers